Pharmaceutical News

RSS

"Knowledge deficit" about methadone responsible for resulting deaths

In a unique and comprehensive literature review of poisoning deaths involving opioids from 1999 -- 2009, the deaths involving methadone were found to be disproportionately high. Methadone represented less than five percent of all opioid prescriptions but is responsible for a third of the deaths. After four years of investigation, the major underlying cause was found to be fundamental misunderstandings about the properties of the medicine -- a "knowledge deficit" -- especially when converting patients from other opioids.

4 Feb 2010

Expert available to discuss Lancet’s retraction of paper on autism study

Rae Sonnenmeier, clinical associate professor of communication sciences and disorders at the University of New Hampshire and staff member at UNH's Institute on Disability, is available to discuss the announcement yesterday (Feb. 2, 2010) by the medical journal The Lancet regarding the retraction of a paper that caused a 12-year international battle over the links between the three-in-one childhood vaccine MMR (measles, mumps, rubella) and autism.

4 Feb 2010

Phase Forward to participate in DIA Workshop and Clinical Trial Supply event

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will participate in two industry events this month: The 13th Annual DIA Workshop in Japan for Clinical Data Management (Booths 4 and 5) and VIB Pharma’s 11th Annual Clinical Trial Supply (Booth 3).

4 Feb 2010

February issue of Chest releases latest medical news

Inhaled corticosteroids (ICS) are widely used for the treatment of chronic obstructive pulmonary disease (COPD). However, new research suggests that ICS may only provide a modest benefit in reducing exacerbations in patients with COPD.

4 Feb 2010

Discussion on IATA Chapter 17 compliance for temperature-sensitive products at 8th Cold Chain Summit

Pharma IQ, a division of IQPC, announces that Kevin O’Donnell Director & CTA of Tegrant Corporation and Chair of IATA’s Time & Temperature Task Force will discuss compliance with IATA’s revised Chapter 17 at the 8th Cold Chain Management and Temperature Control Summit.

From IQPC Ltd 4 Feb 2010

Health Canada accepts AbstralTM New Drug Submission for review

Orexo AB today confirms that its partner, ProStrakan Group plc has announced that the New Drug Submission made by their Canadian partner, Paladin Labs Inc., for AbstralTM has been accepted for review by Health Canada, the Canadian Government Department with responsibility for public health.

4 Feb 2010

Paracetamol reduces damage caused to kidneys following severe muscle injury

The commonly-used painkiller Paracetamol can protect against kidney failure after severe muscle injury, according to research at the University of Essex.

4 Feb 2010

Providing Tamiflu and educating on sanitizer use helped to stop spread of H1N1 at boys' summer camp

Providing preventive Tamiflu and educating and emphasizing the need for repeated hand sanitizer use and disinfectant spray helped stop the spread of H1N1 influenza at a boys' summer camp in northern Alabama, according the co-director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases.

4 Feb 2010

Sermo announces a new report on evolving trends in CML

Sermo, the world's largest online community for physicians, today announced a Sermo Event™ Report titled "Evolving Trends in CML." The new report measures the impact of ENESTnd trial data on Oncologists' use of Tasigna (Novartis), Sprycel (Bristol Myers-Squibb) and Gleevec (Novartis) in newly diagnosed CML patients and assesses overall trends in CML monitoring and management. While Gleevec will likely remain the #1 treatment, there will be a close race for the runner-up spot amongst second-generation tyrosine kinase inhibitors in the front line setting.

4 Feb 2010

New discovery lays foundation for development of new anti-HIV drugs

A team of scientists at The Scripps Research Institute has identified two compounds that act on novel binding sites for an enzyme used by the human immunodeficiency virus (HIV), the virus that causes AIDS.

4 Feb 2010

EUCODIS Bioscience to utilize EUR 2M capital injection for adding enzyme families and development of international markets

EUCODIS Bioscience, a company providing customized enzymes to the pharmaceutical, chemical, and other industries, announced today that it has received a cash injection of EUR 2 million from existing shareholders.

4 Feb 2010

CRN issues statement on "The Dietary Supplement Safety Act of 2010"

The responsible dietary supplement industry represents the health and wellness interests of more than 150 million Americans who use dietary supplements each year. The number one priority for CRN and our members is to ensure that our consumers have access to safe, beneficial products that they can incorporate into their daily wellness regimens.

4 Feb 2010

Ipsen launches Decapeptyl LP 22.5 mg in France

Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.

4 Feb 2010

Vaccination against seasonal influenza produces protective immune response in infants

Vaccination against seasonal influenza is safe and produces a protective immune response in infants as young as 6 to 12 weeks, concludes a study in the February issue of The Pediatric Infectious Disease Journal.

4 Feb 2010

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration (FDA) has approved Xiaflex, a new drug to treat Dupuytren's contracture (or disease) that was discovered and developed by Marie A. Badalamente, Ph.D., and Lawrence C. Hurst, M.D., in the Department of Orthopaedics at Stony Brook University Medical Center.

4 Feb 2010

Study: Generic nifedipine product not bioequivalent to Adalat XL

An extended release generic nifedipine product (Mylan-Nifedipine extended release 60 mg formerly Gen-Nifedipine extended release 60mg, Genpharm ULC) is not bioequivalent to the Canadian originator product, Adalat(R) XL(R), according to the results of a study recently published in the International Journal of Clinical Pharmacology and Therapeutics.

4 Feb 2010

National consensus reached on Joint Technical Statement for drug products

A pan-Canadian initiative was announced today that will ultimately have a major impact on patient safety by reducing preventable medication errors.

4 Feb 2010

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.

4 Feb 2010

New vaccine to prevent malaria infection shown promise to protect young children

A new vaccine to prevent the deadly malaria infection has shown promise to protect the most vulnerable patients - young children - against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development (CVD) and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa.

4 Feb 2010

New York Times examines WHO process for getting H1N1 vaccines to countries in need

The New York Times examines the WHO's role as a "clearinghouse" for getting the H1N1 (swine flu) vaccine to lower income nations. Though H1N1 has died down in North America and many wealthier nations "are trying to get rid of their [vaccine] surpluses," the virus continues to circulate in regions of North Africa, Central Asia and Eastern Europe, according to the newspaper.

3 Feb 2010

Pharmaceutical News

"Knowledge deficit" about methadone responsible for resulting deaths

Expert available to discuss Lancet’s retraction of paper on autism study

Phase Forward to participate in DIA Workshop and Clinical Trial Supply event

February issue of Chest releases latest medical news

Discussion on IATA Chapter 17 compliance for temperature-sensitive products at 8th Cold Chain Summit

Health Canada accepts AbstralTM New Drug Submission for review

Paracetamol reduces damage caused to kidneys following severe muscle injury

Providing Tamiflu and educating on sanitizer use helped to stop spread of H1N1 at boys' summer camp

Sermo announces a new report on evolving trends in CML

New discovery lays foundation for development of new anti-HIV drugs

EUCODIS Bioscience to utilize EUR 2M capital injection for adding enzyme families and development of international markets

CRN issues statement on "The Dietary Supplement Safety Act of 2010"

Ipsen launches Decapeptyl LP 22.5 mg in France

Vaccination against seasonal influenza produces protective immune response in infants

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

Study: Generic nifedipine product not bioequivalent to Adalat XL

National consensus reached on Joint Technical Statement for drug products

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

New vaccine to prevent malaria infection shown promise to protect young children

New York Times examines WHO process for getting H1N1 vaccines to countries in need

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News